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INTRODUCTION 
  Much has been written about Gardasil©, the Human Papillomavirus (HPV) vaccine 
manufactured by Merck (Merck & Co., Inc., Whitehouse Station, N.J.) and approved by the 
Food and Drug Administration (FDA) in 2006
1. Intended to protect recipients from developing 
genital condylomata (warts) and, more significantly, precancerous genital lesions that eventually 
could lead to cancer of the cervix, vagina, and vulva
2, Gardasil© understandably has received 
substantial attention due to its medical merits. However, the manner in which Merck introduced 
Gardasil© to the public caused the vaccine to be surrounded by controversy almost 
immediately
3. Instead of waiting to conduct further safety and efficacy testing, establishing a 
viable system for interested individuals to receive the vaccine at an affordable price, or engaging 
in a widespread educational campaign to teach consumers why the HPV vaccine is necessary, 
Merck pushed ahead with strong lobbying efforts in an attempt to achieve the implementation of 
state legislation making HPV vaccination mandatory. Merck’s political maneuvering led to an 
uproar in some states and eventually motivated the manufacturer to change its strategy and halt 
its lobbying efforts
4.  
                                                           
1 Margaret J. Kochuba, Public Health vs. Patient Rights: Reconciling Informed Consent with HPV Vaccination, 58 
EMORY L.J. 761, 761-62 (2009). 
2 FDA News Release, FDA Approves Expanded Uses for Gardasil to Include Preventing Certain Vulvar and 
Vaginal Cancers, (Sept. 12, 2008), 
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116945.htm 
3 See Stephanie Saul & Andrew Pollack, Furor on Rush to Require Cervical Cancer Vaccine. N.Y. TIMES, Feb. 17, 
2007, at 1; Profit and Public Health: A Useful Vaccine, and a Tone-Deaf Lobbying Campaign on its Behalf, THE 
WASHINGTON POST, Feb. 11, 2007, at B06. 
4 See Amy Gardner, Merck to Stop Pushing to Require Shots, THE WASHINGTON POST, Feb. 21, 2007, at B10; 
Lianne Hart, Uproar Over HPV Vaccine Order, LOS ANGELES TIMES, Feb. 25, 2007, at 25. Hillary W. Steinbrook    Peter Barton Hutt: Food and Drug Law 
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The literature on the HPV vaccine discusses in detail the elements of the controversy 
already outlined above: the lack of extensive testing, high price of the vaccine, and lack of 
knowledge among consumers regarding the connection between HPV and cervical cancer. A 
particularly salient aspect of the Gardasil© debate, the current mandatory status of HPV 
vaccination in some states and pending legislation to the same effect in other states dominates 
the conversation
5. Literature focusing on reactions to the vaccination mandate often considers 
three issues that have become interrelated in this context: rejection of vaccinations, unease 
regarding government mandates, and opposition to interference by drug companies and state 
governments in the sexual activity of pre-adolescent and adolescent girls
6. At times, these issues 
can be conflated and it is difficult to determine exactly what aspect of the HPV vaccination 
mandate has aroused an individual’s anger.  
However, one element of the conversation about the mandate that seems to remain 
constant is the focus on the removal of parental choice. Authors discuss the encroachment of 
governmental activity on parents’ rights to raise their children as they see fit and the difficulty 
faced by parents in opting-out of the HPV vaccination mandate
7. In contrast, much less attention 
has been paid to the attitudes, values, rights, and abilities of the girls and young women who 
have been targeted as Gardasil© recipients. Making HPV vaccination mandatory was hasty, 
given the lack of testing, high price of the vaccine, and lack of knowledge among consumers 
                                                           
5 Gillian Haber, Robert M. Malow, & Gregory D. Zimet, The HPV Vaccine Mandate Controversy, 20 JOURNAL OF 
PEDIATRIC AND ADOLESCENT GYNECOLOGY 325 (2007). 
6 Ellen Goodman, A Dose of Reality on HPV Vaccine, THE BOSTON GLOBE, March 2, 2007, at A19. 
7 See Judy Peres & Bruce Japsen, States Craft HPV Vaccine Bills, CHICAGO TRIBUNE, Feb. 11, 2007, at 3; Liz 
Austin Peterson, Texas Governor Orders HPV Vaccinations for Schoolgirls, CHICAGO TRIBUNE, Feb. 3, 2007, at 4; 
Merck Funds Effort to Pass Vaccine Laws, LOS ANGELES TIMES, Jan. 31, 2007, at 3; Saul & Pollack, supra note 3; 
Haber et al., supra note 5, at 326; Marilynn Larkin, HPV Vaccine Mandate Stirs Controversy in USA, 7 THE LANCET 
251 (2007). Hillary W. Steinbrook    Peter Barton Hutt: Food and Drug Law 
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who could not understand why it was necessary to receive the vaccine. This move also was 
inappropriate. It denied individuals who are competent to make their own medical decisions the 
opportunity to decide whether such a vaccination was medically indicated given their choices 
regarding sexual activity and reasonable based on the level of risk they were comfortable 
assuming. When psychological research on the ability of pre-adolescents and adolescents to 
make medical choices affecting their own bodies is analyzed alongside statutory law governing 
the age of consent in the 50 states, it becomes clear that a vaccine designed specifically to 
combat a disease that results from personal, sexual contact should not have been made the 
subject of a legislative mandate of which only parents could opt out. 
CAUSES, COSTS, AND CONSEQUENCES OF HPV 
  The disease that Gardasil© is intended to prevent occurs in stages. Most women who 
contract HPV will never develop cervical cancer. In many instances, the infection never causes 
symptoms, and the immune system clears the infection before it becomes cancerous. In other 
instances, women contract types of HPV that do not lead to cancer, or they contract types of 
HPV that can lead to cancer but do not actually develop cancer
8. The types of HPV that can lead 
to cervical cancer account for slightly more than 3% of infections
9. HPV is a broad category that 
includes more than 100 viruses, of which approximately 30 are sexually transmitted
10. Of these 
30 types, approximately 90% of genital warts cases are caused by types 6 and 11, and 
                                                           
8 FDA News Release, FDA Licenses New Vaccine for Prevention of Cervical Cancer and Other Diseases in 
Females Caused by Human Papillomavirus: Rapid Approval Marks Major Advancement in Public Health, (June 8, 
2006),  http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108666.htm 
9 Lawrence O. Gostin & Catherine D. DeAngelis, Mandatory HPV Vaccination: Public Health vs. Private Wealth, 
297 JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 1921, 1921 (2007). 
10 Gardasil (Human Papillomavirus Vaccine) Questions and Answers, Vaccines, Blood & Biologics, (June 8, 2006), 
http://www.fda.gov/BiologicsBloodVaccines/Vaccines/QuestionsaboutVaccines/ucm096052.htm Hillary W. Steinbrook    Peter Barton Hutt: Food and Drug Law 
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approximately 70% of cervical cancer cases are caused by types 16 and 18
11. HPV also can cause 
cancer of the vulva, vagina, anus, penis, head, or neck
12; it is HPV’s causal connection to these 
latter four forms of cancer that has contributed in part to efforts to test Gardasil© for efficacy in, 
and promote the vaccination of, boys and men. 
Since effective screening methods for cervical cancer, such as Papanicolaou (Pap) tests, 
already exist in the United States, the physical, emotional, and monetary costs of HPV and 
cervical cancer are more significant in other countries where such screening methods are not as 
readily available
13. Women in the United States who die from cervical cancer usually did not get 
Pap tests
14. Nevertheless, in the United States, HPV still is the most common Sexually 
Transmitted Infection (STI)
15,16. Contracting the infection is strongly associated with the 
female’s number of sexual partners; preventing and treating conditions caused by HPV cost 
approximately $4 billion (2004 dollars) in the United States annually
17. Approximately 6 million 
new cases of HPV are reported annually in the United States
18. More than half of sexually active 
men and women will contract HPV at some point
19; currently, approximately 20 million people 
                                                           
11 Karen Springen, Why Are HPV Vaccine Rates so Low?, NEWSWEEK, (Feb. 25, 2008), 
http://www.newsweek.com/id/115329. 
12 Department of Health and Human Services, Centers for Disease Control and Prevention, Quadrivalent Human 
Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunizations Practices, 56 MORBIDITY 
AND MORTALITY WEEKLY REPORT at 2, (March 23, 2007), http://www.cdc.gov/mmwr/pdf/rr/rr5602.pdf. [hereinafter 
ACIP MMWR] 
13 Elisabeth Rosenthal, Drug Makers’ Push Leads to Cancer Vaccines’ Rise, N.Y. TIMES, Aug. 20, 2008, at 1. 
14 Id. 
15 In this paper, I will use the terms Sexually Transmitted Infection (STI), Sexually Transmitted Disease (STD), and 
Venereal Disease (VD) interchangeably. 
16 Charlotte Haug, The Risks and Benefits of HPV Vaccination, 302 JOURNAL OF THE AMERICAN MEDICAL 
ASSOCIATION 795, 795 (2009). 
17 ACIP MMWR, supra note 12, at 15. 
18 James Colgrove, The Ethics and Politics of Compulsory HPV Vaccinations, 355 THE NEW ENGLAND JOURNAL OF 
MEDICINE 2389, 2389 (2006). 
19 Lisa E. Manhart, King K. Holmes, Laura A. Koutsky, Troy R. Wood, Donna L. Kenney, Qinghua Feng, & Nancy 
B. Kiviat, Human Papillomavirus Infection Among Sexually Active Young Women in the United States: Implications Hillary W. Steinbrook    Peter Barton Hutt: Food and Drug Law 
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in the United States have HPV
20. Among those women who have contracted forms of HPV that 
can lead to cervical cancer, approximately 12,000 develop cancer annually and approximately 
4,000 die from cervical cancer annually
21. In the United States, cervical cancer is the eleventh 
most common form of cancer
22. In contrast, approximately 400,000 new cases of cervical cancer 
occur annually worldwide, and more than 200,000 women die from cervical cancer annually 
worldwide, where cervical cancer is the second most common cancer in women
23.  
Unlike other diseases for which vaccines have been developed, such as smallpox and 
polio, both of which will be discussed below, HPV is transmitted nearly always through 
personal, sexual contact. HPV cannot be transmitted through typical casual, classroom 
interaction even when peers are in close quarters
24. Therefore, the need to vaccinate pre-
adolescent and adolescent girls depends on the manner in which they can contract the infection, 
the time at which they are most likely to contract the infection, and the probability that they will 
do so. In 2007, just under half of all high school students reported having had sexual intercourse. 
The median age of sexual debut is 16.9 years for males and 17.4 years for females
25. In 2000, 
approximately 9.1 million individuals between the ages of 15 and 24 developed new STIs; of 
                                                                                                                                                                                           
for Developing a Vaccination Strategy, 33 SEXUALLY TRANSMITTED DISEASES 502, 502 (2006). [hereinafter 
Manhart et al.] 
20 Melissa Jones & Robert Cook, Intent to Receive an HPV Vaccine Among University Men and Women and 
Implications for Vaccine Administration, 57 JOURNAL OF AMERICAN COLLEGE HEALTH 23, 23 (2008). 
21 Gardasil Vaccine Safety: Information from FDA and CDC on the Safety of Gardasil Vaccine, Vaccines, Blood & 
Biologics, (Aug. 20, 2009), 
http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/VaccineSafety/ucm179549.htm 
22 Robert Steinbrook, The Potential of Human Papillomavirus Vaccine, 354The New England Journal of Medicine 
1109, 1109 (2006). 
23 Centers for Disease Control and Prevention, Vaccine Safety: Information from FDA and CDC on Gardasil and its 
Safety (Archived), (July 22, 2008), http://www.cdc.gov/vaccinesafety/Vaccines/HPV/HPVArchived.html 
24 Haber et al., supra note 5, at 326. 
25 Kaiser Family Foundation, Sexual Health of Adolescents and Young Adults in the United States, (Sept. 2008), 
http://www.kff.org/womenshealth/upload/3040_04.pdf. [hereinafter Kaiser 2008] Hillary W. Steinbrook    Peter Barton Hutt: Food and Drug Law 
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these cases, 51% were caused by HPV
26. Two elements can be drawn from these statistics that 
are particularly important in the debate over making HPV vaccination subject to a mandate of 
which only parents can opt out: barely half of high school students have sexual intercourse, and 
the median age of sexual debut for females is in late adolescence. Moreover, the vast majority of 
adolescents between the ages of 15 and 17 who have never had sex identify concerns about 
contracting STDs and feeling too young as motivations for waiting
27. 
HUMAN PAPILLOMAVIRUS QUADRIVALENT (TYPES 6, 11, 16, 18) VACCINE, 
RECOMBINANT: GARDASIL©  
In June 2006, the FDA approved Gardasil© for use in females between the ages 9 and 26 
to prevent precancerous lesions, cervical cancer, and genital warts
28. Subsequently, the Center 
for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices 
(ACIP) recommended that all girls between the ages of 11 and 12 receive the three-dose 
vaccination series. ACIP chose this age range so that girls could receive the vaccine before they 
become sexually active and exposed to HPV as a result. ACIP based its recommendation on its 
evaluation of data regarding the safety, immunogenicity, efficacy, acceptability, and cost 
effectiveness of the vaccine, as well as data regarding the epidemiology of the underlying disease 
and behavior that could affect the spread of the disease
29. In September 2008, the indications for 
Gardasil© were expanded to include the prevention of vaginal and vulvar cancers, which also 
can be caused by HPV
30. In October 2009, the FDA approved the vaccine for use in males 
                                                           
26 Kaiser 2008, supra note 25. 
27 Kaiser Family Foundation, U.S. Teen Sexual Activity, (Jan. 2005), http://www.kff.org/youthhivstds/upload/U-S-
Teen-Sexual-Activity-Fact-Sheet.pdf. [hereinafter Kaiser 2005] 
28 Gardasil Vaccine Safety: Information from FDA and CDC on the Safety of Gardasil Vaccine, supra note 21. 
29 ACIP MMWR, supra note 12, at 2. 
30 FDA News Release, supra note 2. Hillary W. Steinbrook    Peter Barton Hutt: Food and Drug Law 
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between the ages of 9 and 26 to prevent genital warts
31. Gardasil© is the first vaccine approved 
to prevent these conditions
32. In both the June 2006 Approval Letter and October 2009 Approval 
Letter from the FDA’s Center for Biologics Evaluation and Research (CBER), the director of the 
Office of Vaccines Research and Review acknowledges Merck’s commitment to conduct a 
variety of post-marketing follow up studies on vaccine recipients of both genders to evaluate 
safety and effectiveness. Merck committed to look specifically at pregnancy outcomes, a 
controversial area after the thalidomide tragedy, as well as possible replacement, as a result of 
widespread vaccination, of conditions caused by the four types of HPV against which Gardasil© 
protects with conditions caused by types of HPV against which Gardasil© does not provide any 
protection
33. It is particularly important for Merck to investigate the long-term effects of 
Gardasil©, given the short time frame during which it conducted its initial safety and efficacy 
studies. 
Merck’s vaccine is a recombinant vaccine; since it only contains virus protein, rather than 
the entire virus, Gardasil© cannot cause infection
34. The FDA touts the impressive efficacy of 
the vaccine: it is nearly 100% effective in females in preventing both the precancerous lesions 
caused by HPV types 16 and 18, and the genital warts caused by HPV types 6 and 11
35. In men, 
                                                           
31 FDA News Release, FDA Approves New Indication for Gardasil to Prevent Genital Warts in Men and Boys, (Oct. 
16, 2009), http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm187003.htm 
32 Lindsey R. Baden, Gregory D. Curfman, Stephen Morrissey, & Jeffrey M. Drazen, Human Papillomavirus – 
Opportunity and Challenge, 356 THE NEW ENGLAND JOURNAL OF MEDICINE 1990, 1990. (2007). [hereinafter Baden 
et al.] 
33 See Department of Health and Human Services, Approval Letter – Human Papillomavirus Quadrivalent (Types 6, 
11, 16, 18) Vaccine, Recombinant, Vaccines, Blood & Biologics, (June 8, 2006), 
http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm111283.htm; Department of Health 
and Human Services, Approval Letter – Gardasil, Vaccines, Blood & Biologics, (Oct. 16, 2009), 
http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm186991.htm 
34 Gardasil (Human Papillomavirus Vaccine) Questions and Answers, supra note 10. 
35 FDA News Release, supra note 8. Hillary W. Steinbrook    Peter Barton Hutt: Food and Drug Law 
(02/2010) 
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the vaccine is 90% effective in preventing genital warts
36. Nevertheless, Gardasil© can protect 
against only these four types of HPV
37. Thus, regular Pap screenings still are necessary for 
women
38. Additionally, to achieve optimum effectiveness, the three-dose vaccination series must 
be received before the patient has been exposed to the types of HPV against which Gardasil© 
protects
39. However, ACIP does recommend catch up vaccines for females between the ages of 
13 and 26 who have not begun or completed the series
40, and no adverse effects have been 
reported as a result of receiving the vaccine late
41. More than one quarter of girls in the United 
States between the ages of 13 and 17 has received at least one dose
42. 
Physicians and potential consumers have challenged the wisdom of FDA’s rapid approval 
of Gardasil© after six months through their priority review process
43, raising questions about 
various aspects of the six studies conducted on females before Gardasil© was approved
44. Four 
randomized, double-blind, placebo-controlled studies investigated the safety and efficacy of the 
vaccine in 21,000 females between the ages of 16 and 26
45; these studies established the nearly 
100% effectiveness of the vaccine. However, the recipients of the vaccine were followed for only 
five years after vaccination
46, and cervical, vaginal, and vulvar cancers can be expected to 
                                                           
36 FDA News Release, supra note 31. 
37 FDA News Release, supra note 2. 
38 Gardasil (Human Papillomavirus Vaccine) Questions and Answers, supra note 10. 
39 Baden et al., supra note 32, at 1990. 
40 ACIP MMWR, supra note 12, at 16. 
41 Jones & Cook, supra note 20, at 24. 
42 Sheila M. Rothman & David J. Rothman, Marketing HPV Vaccine: Implications for Adolescent Health and 
Medical Professionalism, 302 JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 781, 781 (2009). 
43 FDA News Release, supra note 8. 
44 Kochuba, supra note 1, at 771. 
45 See ACIP MMWR, supra note 12, at 8-12; Gail Javitt, Deena Berkowitz, & Lawrence O. Gostin, Assessing 
Mandatory HPV Vaccination: Who Should Call the Shots?, 36 J.L. MED. & ETHICS 384, 385 (2008). [hereinafter 
Javitt et al.] 
46 ACIP MMWR, supra note 12, at 11. Hillary W. Steinbrook    Peter Barton Hutt: Food and Drug Law 
(02/2010) 
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develop many years – possibly as long as 20 to 40 years
47 – after exposure to the disease. The 
effectiveness studies were based on the premise that absence of lesions within five years implies 
prevention of cancer
48, a conclusion with which some individuals are not satisfied
49. It is 
important to note that consciously allowing any of the study participants to develop cancer would 
not have been permitted; ACIP explains that “the standard of care is to screen and treat 
[precancerous] lesions to prevent invasive cervical cancer”
50. Additionally, studies of Gardasil© 
indicated that its effectiveness may decrease after three to five years
51. The short time period 
during which the effects of the vaccine were monitored and confirmed has contributed to the 
debate regarding the appropriate age at which receipt of the vaccine should be mandated. When 
the effectiveness of a vaccine intended to protect against an STI has been demonstrated over a 
period of only five years, administering the vaccine to girls as young as 11 and 12 years old may 
be inappropriate
52. 
Additionally, two studies evaluated the immunogenicity response in pre-adolescent and 
adolescent females between the ages of 9 and 15. Since the immune responses were similar in 
both age groups studied, the investigators concluded that effectiveness levels also should be 
similar between the two groups
53. However, some commentators worry that the lack of 
effectiveness testing in this younger age group represents a gap in the data that should have been 
                                                           
47 Haug, supra note 16, at 795. 
48 See FDA News Release, supra note 8; Javitt et al., supra note 45, at 385 (2008). 
49 Baden et al., supra note 32, at 1990.  
50 ACIP MMWR, supra note 12, at 8. 
51 See Rosenthal, supra note 13; David Brown, Millions in U.S. Infected with HPV, THE WASHINGTON POST, Feb. 
28, 2007, at A01. 
52 Rosenthal, supra note 13. 
53 FDA News Release, supra note 8. Hillary W. Steinbrook    Peter Barton Hutt: Food and Drug Law 
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corrected before mandates that apply to members of this cohort were considered and imposed
54. 
Likewise, the effectiveness of the vaccine was studied in 4,055 males between the ages of 16 and 
26, and the immune response was studied in pre-adolescent and adolescent males between the 
ages of 9 and 15. Since the immune responses were similar in both age groups, the investigators 
concluded that effectiveness levels also should be similar between the two groups
55. 
According to the assurances directed to the public by the FDA and CDC, Gardasil© is 
safe, effective, and the subject of continuing analysis through the Vaccine Adverse Event 
Reporting System (VAERS). Vaccine recipients or their family members, healthcare workers, 
and the vaccine manufacturer can submit to VAERS reports of adverse events that take place 
after vaccination occurs. VAERS staff evaluates these reports to determine whether any patterns 
appear in the adverse events that suggest a link between receipt of vaccination and the type of 
adverse event
56. According to a study by the FDA and CDC, the distribution of adverse events 
related to HPV vaccination that were reported to VAERS between June 2006 and December 
2008 were comparable to reports received relating to meningitis and Tdap (tetanus, diphtheria, 
pertussis) vaccines; these vaccines also are recommended for individuals between the ages of 9 
and 26
57. By September 2009, when more than 26 million doses of Gardasil© had been 
administered in the United States, approximately 15,000 adverse events had been reported to 
VAERS. Among the adverse event reports, 93% were non-serious and include syncope 
                                                           
54 Joseph De Soto, Should HPV Vaccination be Mandatory?, 56 THE JOURNAL OF FAMILY PRACTICE 267, 267 
(2007). 
55 FDA News Release, supra note 31. 
56Centers for Disease Control and Prevention, Vaccine Safety: Summary of HPV Adverse Event Reports Published in 
JAMA, (Jan. 15, 2010), http://www.cdc.gov/vaccinesafety/Vaccines/HPV/jama.html 
57 Barbara A. Slade, Laura Leidel, Claudia Vellozzi, Emily Jane Woo, Wei Hua, Andrea Sutherland, Hector S. 
Izurieta, Robert Ball, Nancy Miller, M. Miles Braun, Lauri E. Markowitz, & John Iskander, Postlicensure Safety 
Surveillance for Quadrivalent Human Papillomavirus Recombinant Vaccine, 302 JOURNAL OF THE AMERICAN 
MEDICAL ASSOCIATION 750 (2009), cited in Centers for Disease Control and Prevention, supra note 56. Hillary W. Steinbrook    Peter Barton Hutt: Food and Drug Law 
(02/2010) 
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(fainting), pain and redness at injection site, dizziness, nausea, fever, and headache. The 
remaining 7% were serious; these events include life threatening illness, death, permanent 
disability, or hospitalization. The CDC states that no pattern has been established among the 
deaths that followed receipt of the HPV vaccination
58. Additionally, the CDC explains that no 
link can be drawn between vaccination and Guillain-Barré Syndrome (GBS), a neurological 
disorder that can be caused by a variety of infections
59, although the National Vaccine 
Information Center is not as sanguine about a lack of connection between Gardasil© and GBS
60. 
As the CDC emphasizes, causation cannot be established simply as the result of a temporal 
relationship
61. 
However, syncope and blood clots have been reported in disproportionately high numbers 
after receipt of the HPV vaccine, leading the FDA and CDC to investigate these specific 
conditions further. Many of the individuals who suffered blood clots already were at a higher risk 
for developing clots because they were taking oral contraceptives
62. This potential interaction 
between birth control pills and Gardasil© is particularly frightening because sexually active 
individuals are most likely to both take oral contraceptives and receive the HPV vaccine. 
Furthermore, if efforts to switch oral contraceptives from by prescription only status to over the 
counter status are successful
63, then healthcare workers will need to ask each patient whether she 
is on birth control before administering the vaccine. According to the CDC, syncope commonly 
                                                           
58 Centers for Disease Control and Prevention, Vaccine Safety: Questions and Answers about HPV Vaccine Safety, 
(Jan. 15, 2010), http://www.cdc.gov/vaccinesafety/Vaccines/HPV/hpv_faqs.html 
59 Centers for Disease Control and Prevention, Vaccine Safety: Reports of Health Concerns Following HPV 
Vaccination, (Jan. 15. 2010), http://www.cdc.gov/vaccinesafety/Vaccines/HPV/gardasil.html 
60 Kochuba, supra note 1, at 762. 
61 Centers for Disease Control and Prevention, supra note 59. 
62 Centers for Disease Control and Prevention, supra note 56. 
63 Mayelin Prieto-Gonzalez, Empowering Women: A Feminist Argument for Over-the-Counter Sale of Oral 
Contraceptives (2005), in Peter Barton Hutt, ed., Food and Drug Law: An Electronic Book of Student Papers. Hillary W. Steinbrook    Peter Barton Hutt: Food and Drug Law 
(02/2010) 
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occurs in pre-adolescents and adolescents immediately after receiving a vaccine. However, the 
frequency of reports of syncope was severe enough to motivate the FDA to ask Merck to revise 
the Gardasil© label to remind healthcare workers to watch carefully any vaccine recipient for 15 
minutes after vaccination and recommend that the recipient sit or lie down for this time to avoid 
head injuries from falls
64. None of the reported adverse events has led the CDC to change its 
recommendations or the FDA to change its prescribing information
65. 
STATE RESPONSES 
Within four months after the FDA approved Gardasil© for use in females between the 
ages of 9 and 26, and ACIP recommended administration of the vaccine to girls between the ages 
of 11 and 12, the Michigan Senate already had introduced legislation that would have required 
girls to receive the vaccination before they would be permitted to enter sixth grade
66. In 2006 and 
2007, 41 states and the District of Columbia introduced and considered legislation relating to 
HPV
67. Two more states entered the debate during the 2007-2008 legislative session
68, and 
another state introduced legislation in the 2009-2010 legislative session
69. Three common 
elements can be found in the bills regarding HPV: the provision of educational materials about 
the link between HPV and cervical cancer and the availability of the new vaccine, insurance 
coverage or other methods of funding vaccine administration, and whether the receipt of the 
                                                           
64 Centers for Disease Control and Prevention, supra note 56. 
65 Gardasil Vaccine Safety: Information from FDA and CDC on the Safety of Gardasil Vaccine, supra note 21. 
66 Michigan S.B. 1416; National Conference of State Legislatures, HPV Vaccine, (Feb. 2010), 
http://www.ncsl.org/IssuesResearch/Health/HPVVaccineStateLegislation/tabid/14381/Default.aspx 
67 These states are Arizona, Arkansas, California, Colorado, Connecticut, D.C., Florida, Georgia, Hawaii, Illinois, 
Indiana, Iowa, Kansas, Kentucky, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, 
Nebraska, Nevada, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, 
Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, 
Washington, and West Virginia. National Conference of State Legislatures, supra note 66. 
68 These states are Louisiana and Wisconsin. National Conference of State Legislatures, supra note 66. 
69 This state is Alabama. National Conference of State Legislatures, supra note 66. Hillary W. Steinbrook    Peter Barton Hutt: Food and Drug Law 
(02/2010) 
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HPV vaccine should be made mandatory for girls entering sixth grade when they are most likely 
to be 11 or 12 years old. Although only Virginia and the District of Columbia have enacted 
legislation that currently imposes a vaccination requirement
70, more than 20 other states also 
considered legislation that would have imposed a mandate
71. Most of these states included in the 
legislation that would have imposed an HPV vaccination mandate an opt-out provision to 
provide parents with the option of refusing that their daughters be vaccinated. Arizona
72 and 
Texas
73 took the opposite stance, introducing legislation that would prohibit an HPV vaccination 
mandate. In Texas, legislators acted quickly to override an executive order by the governor in 
February 2007 that mandated HPV vaccination for girls entering the sixth grade
74, the first such 
requirement imposed in the United States
75. More recently, Texas has reconsidered this shift and 
introduced legislation that would allow the imposition of an HPV vaccination mandate
76. 
Conversely, the Virginia legislature is considering whether to remove the vaccination 
requirement
77. Kansas appears to be unique in introducing a resolution directed specifically to 
the FDA, in which the state would urge the FDA to “use caution in approving new vaccines such 
as Gardasil© which has had a number of health problems”
78.  
                                                           
70 Virginia: Va. Chapter No. 922 (2007) and Va. Chapter No. 858 (2007); D.C.: B.17-0030. 
71 These states are California (A.B. 16), Colorado (S.B. 80), Connecticut (H.B. 6977), Florida (S.B. 660), Georgia 
(S.B. 155), Illinois (H.B. 115, S.B. 10), Kansas (H.B. 2227), Kentucky (H.B. 143, H.B. 345, H.B. 396, H.B. 69), 
Maryland (S.B. 54), Massachusetts (Doc 604, S.B. 102), Michigan (H.B. 4164, H.B. 4104, H.B. 5171, S.B. 133), 
Missouri (H.B. 802, S.B. 514), Minnesota (S.F. 243), Mississippi (H.B. 895), New Mexico (S.B. 1174, S.B. 244), 
New York (S.B. 4394, A.B. 5810, A. 778), Ohio (H.B. 81), Oklahoma (S.B. 487), South Carolina (H.B. 3136), 
Vermont (S.B. 256, S.B. 139), and West Virginia (H.B. 2835). National Conference of State Legislatures, supra 
note 66. 
72 Arizona S.B. 1093 
73 Texas H.B. 1098 
74 Texas Executive Order 4 (Feb. 2, 2007) 
75 National Conference of State Legislatures, supra note 66. 
76 Texas H.B. 2220 
77 Virginia H.B. 686 
78 Kansas H.R. 6019 Hillary W. Steinbrook    Peter Barton Hutt: Food and Drug Law 
(02/2010) 
14 
 
  In addition to explicit opt-out provisions provided in some of the HPV vaccination-
specific legislation, all 50 states provide some form of opt-out option regarding vaccination in 
general. Every state offers a medical exemption, allowing a child to avoid vaccination if a 
physician states that the vaccination would harm the child as a result of the child’s physical 
condition
79. Another form of exemption from vaccination, either for religious reasons, 
philosophical reasons, or both, is available in 48 states
80. Only Mississippi and West Virginia do 
not permit either a religious or philosophical exemption to vaccination; both states have declared 
religious exemptions unconstitutional
81. States are not required to provide religious 
exemptions
82. When religious and philosophical exemptions are available, they may be enforced 
inconsistently or require complicated paperwork
83. Some courts have refused to uphold religious 
and philosophical exemptions when they did not believe that the particular claims for exemption 
were valid
84. When a claim for exemption goes unchallenged or is upheld, it may require that the 
individual who is the subject of the exemption not receive any vaccinations
85. As a result of 
inconsistent or overly broad enforcement, some individuals may be deterred from claiming an 
exemption. Consequently, their children will be required to receive a vaccination of which their 
parents do not approve. Alternatively, physicians worry that the addition of a controversial 
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vaccine to the mandatory vaccination regimen may lead parents who are sufficiently motivated 
to avoid this specific vaccine to opt out of having their children receive other vaccinations
86; in 
states with general – as opposed to partial – exemptions, such a situation is the necessary result 
of claiming an exemption to any vaccine. This choice, if made by a sufficient number of 
individuals, could contribute to an increase in incidence of other diseases that can be prevented 
through vaccination
87. Additionally, the creation of an HPV vaccine mandate with broad, 
permissive exemption provisions could set a precedent for legislators to act similarly in the 
future, thereby also contributing to the increase in incidence of preventable diseases
88. 
The vast majority of states permit only a parent or guardian to elect to opt-out of 
vaccinating his or her child
89. The exemption for religious beliefs variably refers to the religious 
beliefs of the child who would be receiving the vaccination or to the beliefs of the child’s 
parents, but it appears that the parent must decide whether to claim the exemption. Several states 
permit an emancipated minor to opt-out of vaccination
90. Louisiana appears to be unique in 
permitting a child to claim an exemption from mandatory vaccination
91. Similarly, Virginia’s 
general vaccination exemption statute seems to allow a child to claim an exemption; however, 
the statute includes a provision explicitly stating that only a parent or guardian may opt-out of 
the administration of the HPV vaccine
92.  Oregon’s vaccination exemption statute is unique in 
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referring to the accepted age of consent to medical care; thus, in Oregon, a parent or guardian, an 
emancipated minor, or an individual over the age of 15 may claim an exemption from 
vaccination
93. Therefore, at least in Oregon, there is recognition of the fact that individuals below 
the age of majority are competent to make decisions regarding which vaccinations they receive. 
However, Oregon still is enforcing an opt-out regime, which is an inappropriate system to apply 
to HPV vaccination. 
Controversy regarding HPV vaccination mandates arose due both to the content of the 
bills and the manner in which they were formulated. Before Merck received FDA approval for 
Gardasil©, the drug manufacturer began to put in place a lobbying campaign to urge state 
legislators to propose bills that would mandate vaccination
94. Merck provided funding directly to 
legislators, including members of the bipartisan advocacy group Women in Government who 
subsequently introduced and advocated for some of the bills at issue that would impose a vaccine 
mandate
95. The relationship between Merck and the government was viewed with particular 
suspicion in Texas, where Governor Rick Perry’s former chief of staff worked as a lobbyist for 
Merck, and Perry received several thousand dollars from Merck’s political action committee
96. 
This connection contributed to the Texas legislature’s outrage over the governor’s executive 
order mandating vaccination
97. On a larger scale, individuals who are wary of drug companies’ 
motives pointed to the enormous profit that Merck stood to make if Gardasil© became a required 
vaccination. Merck’s concurrent competition with GlaxoSmithKline, another drug manufacturer 
that was in the process of developing Cervarix©, also signaled that perhaps Merck was acting 
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out of a desire to win a race to dominate the market rather than protect public health
98. 
Cervarix©, which was approved by the FDA in October 2009, is a vaccine that also protects 
against cervical cancer caused by HPV types 16 and 18
99. The backlash caused by factors related 
to Merck’s methods, rather than Gardasil’s medical merits, dominated media reports covering 
discussions of the pending legislation
100. Realizing that its lobbying activities had become self-
defeating, Merck ended these efforts in February 2007
101. 
Individuals also objected to the speed with which legislation mandating vaccination was 
being considered. Other vaccines intended to protect against common and more easily 
transmitted childhood diseases, such as varicella (chicken pox), became mandated after several 
years of testing and observation
102. Even ACIP, which made the original recommendation that 
girls between the ages of 11 and 12 receive the vaccination, objected to making vaccination 
mandatory once the issue was raised by state legislatures
103. ACIP had not considered making 
the vaccination mandatory
104. The chair of ACIP at the time that the committee had 
recommended vaccination emphasized that prohibiting children from attending school if they 
have not been vaccinated against HPV is inappropriate
105. The American Cancer Society and the 
American Academy of Pediatrics also recommend vaccination but do not support a mandate
106. 
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Providing education seemed to be a more reasonable first step, not only to inform potential 
consumers about the benefits of being vaccinated but also to inform females who lack knowledge 
regarding the underlying disease
107. Less than half of women have heard of HPV, and less than 
half of these women are aware of a connection between HPV and cervical cancer
108. Quickly 
mandating a vaccine that is intended to prevent a mysterious disease would increase distrust for 
drug companies and state governments
109. Recognizing this dilemma, many state legislatures 
have considered bills that instead focus on educational campaigns
110. Ideally, the information 
conveyed through these campaigns will focus strongly on medicine and science, rather than on 
politics
111.  
Any future measures taken regarding the HPV vaccine, including the imposition of 
vaccine mandates, should be formulated and advocated by public health officials and physicians, 
rather than politicians, on the basis of evidence derived from further testing and monitoring
112. 
Unfortunately, advocacy thus far by physician groups for widespread vaccination also has been 
tainted by industry pressures. Merck’s relationship with multiple professional medical 
associations suggests that physicians’ enthusiastic endorsements have been influenced by the 
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substantial funding that Merck provided. Money and biased educational materials went to 
members of the American College of Obstetricians and Gynecologists, American Society for 
Colposcopy and Cervical Pathology, Society of Gynecologic Oncologists, and American College 
Health Association
113. 
  Many articles discussing the negative reactions of parents, conservative groups, and 
religious groups to mandating vaccination against HPV point to parents’ worry that receiving the 
vaccine will encourage teenage sexual activity or at least make teenage sexual activity appear 
acceptable
114. However, studies have demonstrated that the availability of condoms and other 
prophylactics has not led to a rise in adolescent sexual activity
115, an argument also used in favor 
of switching oral contraceptives – particularly those intended for emergency use – from by 
prescription only to over the counter status
116. Furthermore, there are other factors that 
discourage teenagers from engaging in sexual activity, such as the possibility of becoming 
pregnant, contracting HIV, or the emotional and psychological effects that such behavior can 
have
117. There is a subtle difference between the normative and positive implications of 
mandating HPV vaccination that has been overlooked in much of the literature. Requiring that all 
pre-adolescent girls receive Gardasil© is not a statement that adolescents should be sexually 
active but rather is a statement that adolescents will be sexually active. A mandate only makes 
sense if there is a level of inevitability inherent in the condition against which the vaccine is 
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intended to protect
118. Such inevitability appropriately may be attributed to the contraction of an 
illness such as measles or polio among unvaccinated individuals, but it seems to be less 
applicable to a volitional act such as sexual activity. Children often do not know why they 
receive the vaccines that they receive during various visits to the pediatrician throughout 
childhood. If little or no explanation is provided to children regarding why they are vaccinated 
against diphtheria or pertussis, then parents should not necessarily feel that they must discuss 
sexuality with their daughters when their daughters receive the HPV vaccine, an issue that often 
is raised in articles delineating reasons why parents oppose the mandate
119. Given that sexuality 
is a frequent topic of conversation among junior high school students, and is portrayed 
throughout the media, it is unlikely that many parents will be successful in sheltering their 
daughters from any discussion of sexuality until well after the girls’ eleventh or twelfth birthday. 
However, receipt of the HPV vaccine should not necessitate a discussion about sexual activity.  
Therefore, it seems more likely that parents actually are angered by the assumption that 
has been made by the government; in effect, states proposing mandates have concluded that 
adolescent girls will be sexually active and therefore must be inoculated beforehand to protect 
them from themselves. Such a policy exceeds states’ powers to set vaccine mandates, denies the 
variability among adolescent behavior, and places too much authority in parents’ hands to 
determine what is appropriate sexual behavior for their daughters. In some instances, parents 
may not consent to their daughters receiving the HPV vaccine when it actually should be 
administered, given the daughters’ choices regarding their future behavior. In other instances, 
parents who support vaccination against HPV may believe that their daughters should be 
                                                           
118 Charo suggests that such inevitability in fact exists. Charo, supra note 115, at 1907. 
119 Haber et al., supra note 5, at 328. Hillary W. Steinbrook    Peter Barton Hutt: Food and Drug Law 
(02/2010) 
21 
 
vaccinated based on the parents’ own views of reasonable sexual activity, regardless of their 
daughters’ intentions. It would seem reasonable for a daughter in the latter category to interpret 
her parents’ decision as a belief that adolescents will engage in sexual activity, a conviction that 
may conflict with the daughter’s own moral, philosophical, or religious beliefs. 
Of course, Merck would prefer that all females between the ages of 9 and 26 receive 
Gardasil©; consequently, the manufacturer is not going to encourage these individuals to think 
about whether they actually will need the vaccine based on their intended level of sexual activity. 
However, in its advertising campaign “One Less,” Merck did take into consideration the 
importance of allowing minors to have a voice in the decision whether to get vaccinated, which 
their parents have the legal authority to make
120. In one television spot, highlighted in a New 
York Times article from 2007
121, female adolescents engage in high-energy activities such as 
skateboarding, playing the drums, and playing basketball and soccer. These individuals are 
assertive and know how they want to protect themselves. After 23 seconds of the minute-long 
commercial, a middle-aged woman, ostensibly a mother, finally appears on the screen to describe 
the side effects of the vaccine
122. It is clear that Merck is aiming its message directly at daughters 
in this advertisement. In contrast, a second English-language television commercial and a 
Spanish-language commercial focus on racially diverse mother-daughter relationships. The 
Spanish-language advertisement portrays mothers and daughters shopping for clothes and 
participating in cultural performances and other artistic activities
123. Likewise, the second 
English-language advertisement portrays happy, active women and their daughters engaging in 
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similar activities
124. A third English-language advertisement features eight confident, 
independent young women who all appear to be in their twenties and who suggest that the viewer 
get vaccinated as they did
125.  
There is no mention of sex in any of these four commercials, and no men appear in the 
advertisements, aside from an image of a father that remains on the screen for a second or two in 
the first English-language commercial. Anyone who views these commercials and does not 
already know the source of HPV will not be able to determine its mode of transmission from the 
advertisements. Thus, these television spots avoid any suggestion that receipt of the vaccination 
will encourage promiscuity. However, by focusing on the prevention of cervical cancer, rather 
than its precursors or the behavior that leads to exposure, the advertisements also suggest that the 
vaccine is necessary for all girls. Rothman and Rothman suggest that such a marketing ploy is 
ethically inappropriate
126, while Jones and Cook explicitly state that it is unwise
127. The “One 
Less” campaign clearly was geared towards females only, but pre-adolescent and adolescent 
males also are expected to become a target audience. Jones and Cook found that males 
understandably are more likely to accept a vaccine that is promoted as protecting against both 
genital warts and cervical cancer, rather than a vaccine that prevents only cervical cancer
128. 
Nevertheless, Gardasil© won pharmaceutical marketing and advertising awards
129. 
 
 
                                                           
124 This advertisement is available on YouTube: http://www.youtube.com/watch?v=15Jk3OBm3lU&feature=related 
125 This advertisement is available on YouTube: 
http://www.youtube.com/watch?v=ZHUamYNSH9c&feature=related 
126 Rothman & Rothman, supra note 42, at 781-82. 
127 Jones & Cook, supra note 20, at 28.  
128 Id. 
129 See Rothman & Rothman, supra note 42, at 781; Rosenthal, supra note 13. Hillary W. Steinbrook    Peter Barton Hutt: Food and Drug Law 
(02/2010) 
23 
 
ABILITY TO ENFORCE MANDATORY VACCINATION 
  Under the Tenth Amendment to the United States Constitution, the states are granted 
police powers, which include protection of the public health and welfare
130. Although vaccines 
are approved and recommended at the federal level, states can determine which vaccinations 
must be administered to individuals at various ages; states often look to these federal 
recommendations when instituting vaccination requirements
131. Therefore, states can establish 
school vaccination mandates for those vaccines the receipt of which is deemed to be a necessary 
precondition to entering a particular grade in school. For example, according to the National 
Vaccine Advisory Committee (NVAC) of the Department of Health and Human Services, as of 
2005-2006, 21 states required receipt of the tetanus and diphtheria vaccine, 47 states required 
receipt of the measles vaccine, 33 states required receipt of the hepatitis B vaccine, and 24 states 
required receipt of the varicella vaccine before entering junior high school
132. 
However, the Supreme Court has set limits on the types of diseases that can serve as the 
basis for a mandatory vaccination law. Literature discussing the constitutional validity of the 
HPV vaccine mandate relies heavily on Jacobson v. Massachusetts, 197 U.S. 11 (1905), in which 
the Supreme Court first delineated the requirements for a valid vaccination mandate; here, the 
disease at issue was smallpox
133. The exercise of state police powers must be reasonable, 
justified by the circumstances, and intended to protect the community rather than only the 
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recipient of the vaccine, a condition now known as herd immunity, for the court to uphold this 
form of impingement of individual liberty. Jacobson, 197 U.S. at 27-29. Zucht v. King, 260 U.S. 
174, 176 (1922), extended Jacobson to apply to school vaccination mandates. In the later case In 
re Christine M., 595 N.Y.S.2d 606, 613, 618 (N.Y. Fam. Ct. 1992), the Court emphasized that 
for a vaccine to be mandated, it also must be necessary. Some authors deem this condition to be 
lacking in the case of HPV due to the low incidence of harm, slow rate of disease development, 
and volitional mode of transmission, among other factors
134.  
HPV variably is compared to polio, smallpox, and measles throughout the literature. Each 
of these illnesses has been virtually eradicated through mandatory vaccines, but none provides an 
appropriate analogy to HPV
135. Polio, smallpox, and measles are highly contagious diseases that 
can spread rapidly through the public and kill many individuals. By vaccinating nearly everyone 
against these scourges, the United States has achieved herd immunity against each. Even if an 
unvaccinated individual is present in the population, the vast majority of individuals have been 
vaccinated; as a result, the unvaccinated individual is not at risk of contracting a disease that 
cannot spread. Some articles discussing whether an HPV vaccine mandate is appropriate state 
that such a vaccination eventually will lead to herd immunity
136, while others assert that the 
vaccine is intended to protect only the recipient
137, and therefore is not the proper focus of a 
vaccine mandate. In addition, since Gardasil© only protects against a subset of HPV types, 
widespread vaccination could not achieve complete herd immunity
138. Even if it is theoretically 
possible to achieve herd immunity against some forms of HPV, another divide in the literature 
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arises regarding whether it is reasonable – scientifically or constitutionally – to mandate 
vaccination for girls only, or if boys must be vaccinated as well to achieve such immunity at the 
population level
139 and avoid Equal Protection Clause violations
140. Gardasil© is the first vaccine 
to be the subject of a mandate that applies only to one gender
141. Cervical cancer afflicts only 
females, but males and females are equally vulnerable to HPV infection, and most females 
contract HPV from their male sexual partners
142. Since vaccination of males may be indicated, 
and Gardasil© has been approved for use in males, it appears that waiting to push for vaccination 
mandates until these mandates reasonably could have been applied to both genders would have 
avoided this part of the conflict and also cut in half the amount of time and effort necessary to 
deal with the legislative process
143. Although this paper focuses on the ability of pre-adolescent 
and adolescent females to make their own competent medical decisions, the same arguments 
apply to pre-adolescent and adolescent males. 
In addition to the absence of a public health necessity that could justify any form of HPV 
vaccine mandate, many commentators point to the lack of a reasonable relationship between 
vaccination against HPV and school attendance. Unlike airborne illnesses, HPV cannot be 
transmitted through normal, casual classroom contact. There is no inherent connection between 
the spread of HPV and school attendance
144. Admittedly, a school vaccine mandate likely will be 
more successful, in terms of rate of vaccine uptake, than a voluntary policy and educational 
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campaign
145. The NVAC, among others, bemoans the infrequency with which adolescents seek 
and receive preventive medical care, which presents an obstacle to widespread vaccine 
administration
146. However, even students who are not at risk of contracting HPV as a result of 
their behavioral choices could be excluded from school if they are not vaccinated, according to 
the provisions in several states’ proposed legislation. 
Implementing an HPV vaccine mandate as a condition for school attendance also has 
been challenged as an illegal intrusion into parents’ rights to raise their children, a view with 
which the American College of Pediatricians agrees
147. Parents have a fundamental due process 
right under the Fourteenth Amendment to make decisions regarding upbringing without 
interference by the state
148. This right is limited, however, when the decision at issue could lead 
to substantial harm to the children or other individuals, in which case the state may exercise its 
parens patriae authority to intervene on behalf of the child
149. Clearly, such harm would not 
occur if parents, or preferably the pre-adolescents or adolescents themselves, chose to reject 
vaccination against HPV. An individual can avoid contracting HPV by behaving in a particular 
manner. Even if the individual engages in sexual activity, she will not necessarily contract HPV. 
Furthermore, most HPV infections are asymptomatic, and of those cases that do lead to 
symptoms, most will not lead to cancer. A decision not to vaccinate will not lead to irreparable 
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harm either to the individual who would be receiving the vaccine or to her peers. Thus, there is 
no danger that must be avoided by ordering receipt of a vaccination of which parents do not 
approve
150. Nevertheless, it is possible that the force and speed with which mandates have been 
proposed – and two successfully have been enacted – may cause parents to feel pressured to have 
their daughters vaccinated
151. Throughout the debate regarding parents’ right to make decisions, 
little attention has been paid to the individuals who will be affected most by the decision: the 
daughters. 
PRE-ADOLESCENT AND ADOLESCENT COMPETENCY TO MAKE MEDICAL DECISIONS 
In general, parents have the authority to grant or withhold consent to the voluntary 
medical treatment of their minor offspring
152. However, in addition to setting the age of majority 
and the age at which minors can enter into contracts, most states also establish the age at which 
minors can consent to medical treatment or the conditions under which they can consent to such 
treatment regardless of age. Typical conditions include whether the minor is married, in the 
military, or emancipated
153. These minimum age requirements often do not deal with 
withholding consent, an issue that is particularly important in the context of a mandate. These 
requirements also are separate from provisions governing the ability to opt-out of receiving a 
mandatory vaccination. Mandatory vaccination rules limiting to parents and guardians the ability 
to opt-out of receiving the vaccine may be appropriate regarding vaccines that protect against 
severe airborne illnesses. Minors are unable to avoid airborne illnesses through typical classroom 
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behavior, so there is no personal choice involved in whether an individual contracts the illness at 
issue. However, such rules should be applied only to vaccines unrelated to sexual activity. 
An evaluation of the states’ laws regarding the minimum age of consent to medical 
treatment reveals an apparent consensus that consent regarding issues related to sexual activity is 
different from consent regarding other ailments and conditions. Many states provide separate 
provisions specifically governing consent for the diagnosis, treatment, and prevention of VDs 
and STDs; these provisions often do not set a minimum age for providing consent and do not 
require parental notification or approval. For example, Kansas has at least three statutory 
sections governing medical consent by minors: an unmarried and pregnant minor may give 
consent to medical treatment regardless of age
154, a minor above the age of 16 may give consent 
to medical treatment
155, and any minor may give consent with regard to the diagnosis and 
treatment of a VD
156. Similarly, in Oregon, an individual above the age of 15 may consent to 
medical treatment, and a minor of any age may consent to the diagnosis and treatment of a 
VD
157. In Texas, an individual above the age of 16 who is living apart from his or her parents 
and managing his or her own finances may give valid consent, but any minor regardless of age 
may consent to treatment for an infectious disease
158. Alabama
159, Alaska
160, Arizona
161, DC
162, 
Hawaii
163, Indiana
164, Louisiana
165, Maine
166, Maryland
167, Michigan
168, Minnesota
169, 
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Missouri
170, Montana
171, Nevada
172, New Jersey
173, North Carolina
174, Oklahoma
175, South 
Dakota
176, and Virginia
177 allow minors of any age to consent to treatment related to a VD. 
Additionally, California
178, Idaho
179, Illinois
180, North Dakota
181, and Vermont
182 set minimum 
age limits for the provision of medical consent regarding diagnosis, treatment, and prevention of 
a VD well below 18. The law in Arkansas also reflects a form of the mature minor exception; 
any minor who is “sufficiently intelligent to understand the consequences” of the medical 
treatment requested may consent
183. Admittedly, vaccination against HPV is intended to prevent, 
not treat, an STI. However, states have recognized not only that rules regarding VDs should be 
separate from those regarding other forms of medical care, but also that minors are competent to 
make decisions regarding treatment for a VD. In terms of prevention, Colorado
184, Hawaii
185, 
Maryland
186, Oregon
187, Tennessee
188, and Virginia
189 permit minors of any age to request and 
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receive information and services related to birth control and family planning. Moreover, a minor 
need not notify her parents or obtain their consent before buying condoms or other over-the-
counter contraceptives
190. Minors’ use of contraceptives and its relation to unwanted pregnancies 
and abortions entail a host of other complicated issues. Nevertheless, the apparent determination 
by some states that minors are capable of making informed, competent decisions about 
contraceptives signals a belief that personal choice is a necessary element of sexual behavior. 
Legal commentators state that the separation of sexually-related medical issues from 
other medical conditions within the realm of consent rules cannot be taken as evidence of a belief 
by states that adolescents actually are competent to make decisions regarding their medical care 
for sexually-related medical issues. Instead, rules allowing minors to consent to their own 
treatment for VDs were enacted to provide minors with the privacy that was considered 
necessary for minors to seek out treatment for these conditions. State governments were 
concerned that VDs would spread more widely if minors were required to notify their parents or 
obtain their parents’ consent before receiving treatment for VDs, because minors were more 
likely to avoid medical treatment altogether if such a requirement were in place. Thus, 
adolescents are deemed mature in this narrow context out of necessity, rather than as a result of 
any true belief that adolescents are capable of making such decisions
191. Given the growing body 
of psychological literature supporting the competency of pre-adolescents and adolescents to 
make medical decisions, it seems reasonable that the rules at issue could be endowed with an 
additional justification even if that were not the original justification. Studies of adolescents’ 
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decision-making capabilities only support the wisdom of these rules regarding consent for 
treatment for VDs. Furthermore, allowing pre-adolescents and adolescents to grant or withhold 
consent for vaccination against HPV would support both the privacy-based rationale and the 
competency-based rationale that can be assigned to these rules. Assuming that the rules are based 
on privacy, allowing minors whose parents do not want them to be vaccinated to consent to 
receipt of the vaccine without needing to notify their parents or obtain their parents’ consent 
would support the public health goal of preventing the spread of STIs. Conversely, allowing 
minors whose parents want them to be vaccinated to withhold consent because they do not need 
the vaccine also would promote the privacy of individuals who may feel pressured by their 
parents to behave in a manner with which they do not agree but who do not feel comfortable 
discussing with their parents their decision not to engage in sexual activity. 
The ages set for considering an individual an adult, or at least competent to make specific 
types of decisions, often appear to be arbitrary. For instance, California
192, Illinois
193, and 
Vermont
194 allow minors above the age of 12 to consent to medical care related to the diagnosis 
and treatment of an STD, while Idaho
195 and North Dakota
196 set 14 as the appropriate age. 
Similarly, a variety of ages have been set as appropriate minima for drinking, driving, and 
viewing an R-rated movie, for example. However, when the psychological capabilities of pre-
adolescents and adolescents are evaluated, varying age limits associated with different activities 
appear more logical
197. 
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The American Psychological Association (APA) recently came under fire as a result of 
its apparently inconsistent views on the maturity of adolescents. The APA authored an amicus 
brief in the Supreme Court case Hodgson v. Minnesota, 497 U.S. 417 (1990), in which the APA 
argued that adolescents’ mature cognitive abilities make them capable of making an independent 
decision to have an abortion, even at age 14. Specifically, the APA stated that 14-year-olds are 
capable of “understanding treatment alternatives [and] considering risks and benefits”
198. Several 
years later, the APA asserted in its amicus brief in the Supreme Court case Roper v. Simmons, 
543 U.S. 551 (2005), that adolescents’ emotional and social immaturity militate against allowing 
the death penalty for juveniles at age 16 or 17
199.  
In an effort to demonstrate the consistency of these apparently incongruent arguments, 
Steinberg et al. present and discuss data supporting the APA’s overarching view that 
adolescents’ cognitive abilities mature faster than their emotional and social abilities. During 
adolescence, an individual may be as mature as an adult with regard to consideration of moral 
issues but still may lag far behind adults in terms of impulsivity and vulnerability to peer 
pressure. As a result, it is appropriate to treat adolescents as adults in some contexts but not in 
others. Cognitive abilities are deemed to be fully matured by age 16, but adolescents’ emotional 
and social abilities are not equivalent to those of adults even at age 18. The authors point out that 
many adolescents who consider obtaining an abortion without their parents’ knowledge seek 
advice from an adult such as a teacher, counselor, or member of the clergy. In many states, 
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women who are seeking an abortion must receive counseling before obtaining the procedure, and 
some states impose a waiting period between the receipt of counseling and the initiation of the 
procedure to allow the prospective patients to consider their options in an informed manner. 
Steinberg et al. emphasize the importance of allowing individuals to receive information and take 
time to think about the information before making this medical decision, which also is relevant in 
the debate over receiving the HPV vaccine. In the context of medical decision making in general, 
individuals often have the opportunity to engage in “deliberative, reasoned decision making” and 
converse with “consultants [health care practitioners] who can provide objective information 
about the costs and benefits of alternative courses of action”
200. Furthermore, the authors state 
that the adults involved in consulting with the adolescent who must make the medical decision 
“cannot and should not make the decision for the adolescent”
201. Whether this individual is a 
health care practitioner, parent, or other adult, Hartman concurs that adolescents benefit from 
having the opportunity to converse with an adult whom the adolescent trusts before making a 
treatment regarding medical care
202. 
  Providing pre-adolescent and adolescent girls with the opportunity to learn about HPV 
and the options they have for avoiding infection is both consistent with the girls’ capabilities and 
supports their autonomy. Steinberg and Cauffman delineate in their literature review on 
adolescent maturity of judgment three categories of psychosocial factors that influence decision 
making. One of these categories is responsibility, which includes autonomy. Disagreeing with 
standard definitions of autonomy that focus on independent decision making, the authors state 
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that individuals who have developed mature judgment “know[] where to turn for advice, know[] 
how to solicit it, and know[] whether and to what extent to follow it”
203. This ability improves 
throughout adolescence. 
  However, other research suggests that children even as young as 9 can provide a 
competent voice in their own medical decisions. Weithorn and Campbell sought to determine 
and compare the level of competence to make medical decisions demonstrated by individuals 
ages 9, 14, 18, and 21. Four aspects of competency were measured: ability to make a choice 
among alternative possible treatments, reasonable outcome, rational reasoning that contributed to 
the choice made, and understanding of risks and benefits. Understanding was subdivided into 
comprehension of the facts of the situation and appreciation of the consequences of the choice on 
the individual. As it was defined here, competency requires formal operational thought, which 
develops in children growing up in Western cultures between ages 11 and 14. As the authors had 
hypothesized, 14-year-olds were as competent as adults on all four aspects of competency. While 
9-year-olds had more difficulty demonstrating rational reasoning that contributed to the choice 
made and an understanding of risks and benefits, these children were competent regarding ability 
to make a choice and a reasonable outcome of that choice
204. Therefore, even if ACIP states, and 
researchers conducting cost-effectiveness studies advocate
205, that 11- and 12-year-old girls are 
the proper recipients of the HPV vaccine, it would be more appropriate to allow these girls to 
participate in the decision making process regarding whether they should receive the vaccine. 
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  The findings reported in developmental psychology literature are consistent with the 
views of healthcare providers who interact with adolescent patients. Hartman surveyed 173 
pediatricians, family practitioners, and internists about their perceptions of adolescent patients. 
Most of these physicians agreed that these patients “understand information about medical 
treatment and conditions, engage in rational deliberation during the decisional process, and 
communicate choices and concerns clearly”
206, all of which are factors that Weithorn and 
Campbell addressed directly in their study of the abilities of pre-adolescents and adolescents. 
Hartman’s data reflect the opinions of physicians who have evaluated their cumulative 
experiences retrospectively, rather than being asked to respond to survey items during real-time, 
individual interactions. However, Hartman’s data are valuable because they describe adolescent 
behavior in the relevant environment. This study suggests that adolescents are capable of making 
competent medical decisions not only in the context of depersonalized hypothetical scenarios but 
also in the more stressful setting of a doctor’s office. 
Literature on HPV vaccination often does not consider that the views of parents may 
conflict with the views of their daughters. When authors do confront such a dilemma, they 
assume that parents would not want their daughters to receive the vaccination while the girls 
actually would want to be vaccinated. For instance, Balog asserts that “the right of the child to 
receive the preventive measure should override respect for the parents’ autonomy and the 
parents’ desire to teach social beliefs that restrict health care action, because the health threat 
directly involves the life of the child”
207. This argument supports the ability of the pre-adolescent 
or adolescent female to choose whether to receive the vaccination, but it also goes too far. Some 
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targeted recipients likely will not want to receive the vaccine or feel that they do not need it, 
given the choices they intend to make regarding their level of sexual activity, but their parents 
will support vaccination. In states where vaccination has been mandated, the parents’ views carry 
little weight. However, in states where vaccination has not yet been mandated, parents will be 
able to decide whether their daughters should be vaccinated, regardless of their daughters’ views. 
Bills that suggest that information about HPV and cervical cancer be promulgated, rather 
than immediately mandating receipt of the HPV vaccine, are preferable for a number of reasons. 
Conflict between the state and parents who feel that their rights are being threatened will be 
minimized, many individuals will increase their knowledge about an important public health 
issue, and students will be allowed to continue to attend school while individual families 
consider the costs and benefits of vaccination. However, it is important to consider to whom the 
information is being directed
208. In formulating its advertising strategy, Merck understood that in 
states without mandates, the company needed to convince pre-adolescent and adolescent girls 
that they would benefit from the vaccine. Once members of this targeted audience became 
supporters of Merck’s campaign, they would request their parents’ consent to receive Gardasil©. 
Admittedly, Merck’s motives likely were more commercial than benevolent. However, an 
examination of the bills proposed in legislatures across the country suggests that many of the 
states did not similarly recognize the importance of educating the individuals who actually would 
be receiving the vaccine. Instead, states such as Colorado
209, Florida
210, Georgia
211, Hawaii
212, 
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Illinois
213, Indiana
214, Kansas
215, Minnesota
216, Missouri
217, New Jersey
218, New Mexico
219, New 
York
220, North Carolina
221, and Washington
222 indicated that new educational materials 
discussing HPV and cervical cancer should be directed to parents and guardians
223. Neglecting to 
provide educational materials to pre-adolescent and adolescent girls belies the girls’ ability to 
understand and denies them the opportunity to learn directly about medical issues that affect 
them. As the NVAC emphasizes, gearing information directly towards adolescents is especially 
important in the case of a vaccine intended to protect partially – but not fully – against an STI, 
since recipients of the vaccine must be warned that they still will need to rely on other forms of 
protection. Moreover, informational materials aimed at adolescents likely will need to adopt a 
different tone from those aimed at parents and guardians
224. 
Legal literature on the competency of minors to make decisions regarding their own 
medical treatment generally does not discuss vaccination policy but rather focuses on voluntary 
interventions for conditions that afflict an individual rather than those that have the potential to 
harm a community. Since these opt-in therapies require parental consent, the authors can analyze 
whether it is appropriate to require such consent regardless of the type of treatment at issue, or if 
minors should be allowed to exert some influence over their own treatment in some 
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circumstances. This paper focuses on a treatment for which parents already must – or likely soon 
will need to – opt out in some states, but which is voluntary in other jurisdictions. Therefore, the 
arguments presented in the legal literature also can be applied to the Gardasil© vaccination 
policies. Relying on research in the field of developmental psychology to support their 
conclusions, Arshagouni, Austin, Hanisco, Hartman, and Rosato all advocate a shift in the law 
that would grant more authority to minors over their own medical treatment. These authors point 
to a growing body of work in both the legal and medical arenas that push for similar proposals. 
Arshagouni would divide medical procedures into two categories: those that are routine 
and low-risk without potential adverse long-term consequences, and those that are high-risk or 
have potential adverse long-term consequences. He would grant a “presumption of capacity” to 
make decisions among adolescents with regard to the former, and a “rebuttable presumption of 
no decisional capacity” with regard to the latter
225. The author emphasizes not only the progress 
that has been made in scientific understanding of the ability of adolescents to comprehend 
medical dilemmas, but also the importance of allowing adolescents to develop the ability to 
make decisions based on that comprehension. He states that removing reasonable opportunities 
for adolescents to exercise decision-making capacity “inhibits development” of these skills
226. As 
a result, adolescents’ current abilities are denied and their future capabilities may be stunted. 
Arshagouni and Hartman both explain that the promotion of healthy brain development and an 
attitude of self-efficacy and self-respect among a generation of adolescents who will need to 
grow into confident and competent adults require giving these adolescents the opportunity to 
make decisions within the context of routine medical care. 
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Arriving at a similar conclusion regarding the types of medical procedures for which 
minors should be able to provide their own consent, Austin evaluates a variety of psychological 
studies. Acknowledging that competency develops in different contexts at different rates, Austin 
rejects the “all-or-nothing standard” imposed by law as inconsistent with psychological reality
227. 
As Weithorn and Campbell indicated, courts consider several elements when making 
competency determinations, such as a basic ability to communicate, recognition of the current 
situation, comprehension of possible treatments, and an understanding of consequences of those 
options. Summarizing the data, Austin states that adolescents age 14 and older demonstrate 
adult-level competence with regard to these factors in the context of medical treatment. 
According to Hanisco, physicians who often have minor patients disagree with the 
current law on consent to such a degree that the American Academy of Pediatrics Task Force has 
promulgated guidelines on this subject. The guidelines suggest that a physician should obtain the 
written consent of a minor age 13 or older for elective surgery or other treatment, and a minor 
over age 7 also should be included in the decision-making process. Pediatricians should conduct 
individualized assessments of the patient’s capabilities in relation to the severity of the condition 
and risks and benefits of the treatment options when deciding whether a minor over age 7 
reasonably can understand the decision that must be made
228. These guidelines are consistent 
with behavior noted by Hartman in her study of physicians’ perception of adolescents’ abilities, 
discussed above. Specifically, Hartman states that many pediatricians believe that “the law 
should defer to medical judgment about adolescent decisional capacity.” In other words, instead 
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of allowing the law to impose a blanket presumption of incompetence from the outside, 
pediatricians would prefer to have the independence to make individualized assessments of pre-
adolescent and adolescent competence within the practice of medicine; such assessments likely 
would establish the competence of many of these patients. 
Although Rosato is not as generous as other authors in terms of arguing for the provision 
of decision making authority to minors in the context of “ordinary health care decisions”
229 (as 
compared to abortion, “life-sustaining treatment decisions,” and “decisions with no direct 
physical benefit to the child,” none of which is at issue here), she does advocate for a 
“participatory model”
230. The minor should be included in the process because doing so would 
promote “competence and moral development”
231. Echoing Hartman, Rosato also states that 
“allowing adolescents to make health care decisions is beneficial because it is likely to improve 
their self-esteem and sense of control in the short-term, and make them better decision-makers 
and citizens in the long-term”
232. Rosato also asserts that “the failure to respect adolescents’ 
burgeoning autonomy is likely to cause harm to their personhood, especially when the health 
care decision involves the exercise of moral judgment”
233; this statement that is particularly 
relevant in the context of a medical issue related to sexuality. 
ALTERNATIVE COURSES OF ACTION 
Merck likely could have avoided much of the negative press that it received in relation to 
the promotion of Gardasil© if it had adopted an alternative strategy. Merck’s push to make HPV 
vaccination mandatory soon after the vaccine was approved by the FDA alienated both the 
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parents of targeted girls and the physicians who would be expected to administer the vaccine. In 
states where vaccination has not been mandated, physicians have been reluctant to encourage 
parents to allow their pre-adolescent and adolescent girls to receive the vaccine, out of fear of 
parents’ responses
234. Certainly, a successful mandate would create automatically a large market 
for Merck’s vaccine. However, providing girls with the choice of whether to get the vaccine 
through an opt-in system likely could have avoided the outrage over the mandate that occurred in 
some states and still have led to financial success for Merck. 
Girls who have been educated about the prevalence of HPV, the link between HPV and 
cervical cancer, and the protection that a vaccination against HPV can provide are more likely to 
voluntarily seek vaccination than girls who are not as knowledgeable about these issues. Within 
their sample, Jones and Cook found that 77.5% of male college students and 88.6% of female 
college students were willing to receive an HPV vaccine. Both level of knowledge about HPV 
and level of self-reported sexual activity were significantly related to intent to receive the 
vaccine. Specifically, students who had had sex, and students who reported having more than 
five sexual partners, were significantly more likely to indicate an intention to receive the vaccine 
than their sexually inexperienced peers
235. On the one hand, these data can be interpreted to 
suggest that sexually inexperienced adolescents and young adults, once they have received more 
education regarding HPV, also will be eager to receive the vaccine, as Jones and Cook suggest. 
On the other hand, the same data simply could reflect the students’ self-awareness regarding 
their future sexual behavior. A student who does not intend to become sexually active in college 
may not feel the need to receive the vaccine regardless of the amount of educational material that 
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she receives. However, students who are sexually active or intend to become sexually active in 
college would benefit from increased education. 
Furthermore, adolescents and young adults who support vaccination against HPV may be 
eager to spread the word to their friends. In 2006, Harvard University Health Services (HUHS) 
began providing Gardasil© to Harvard students. Soon thereafter, 15 Harvard student 
organizations, including the Harvard College Women’s Center, began the Harvard HPV Vaccine 
Awareness Campaign to lead education efforts on campus and communicate with HUHS about 
subsidizing the vaccine. Within a year, HUHS implemented a two-year program that reduced the 
price of the three-dose vaccination series from $462 to $75. Before HUHS offered the reduced 
price, 141 students received the three doses from HUHS and 403 other students received at least 
one of the doses from HUHS. By May 2009, HUHS reported that 1,126 students had received all 
three doses and another 1,237 students had received at least one dose from HUHS. Support from 
HUHS for subsidized vaccines has ended, due to the increased availability of the three-dose 
series to females before they enter college. However, education efforts by student groups 
continue on campus
236, suggesting that Merck could have found success by appealing to peer 
networks. 
If a mandate were the only acceptable course of action for Merck, then the targeted pre-
adolescent girls should have been given the opportunity to opt-out of receiving the vaccination 
themselves. As discussed above, individuals within the targeted age group are competent to 
make decisions regarding medical conditions at this level of severity. State laws governing age 
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of consent to medical treatment often apply only to affirmative consent to the receipt of 
treatment rather than the decision to withhold consent and reject medical treatment. However, 
this distinction is neither psychologically appropriate nor legally necessary.  
Furthermore, a mandate with a strong opt-out provision might have led to the provision 
of the vaccination series at an acceptable price while simultaneously achieving a reasonable 
balance between individual autonomy on the one hand and racial and socio-economic targeting 
on the other. A vaccine that has been mandated is more likely to be covered by dedicated funding 
at the state level and vaccination programs at the federal level than a vaccine that is optional
237. 
Such programs include the federal Vaccines for Children Program (VFC), which provides free 
vaccines to children between the ages of 9 and 18 who are covered by Medicaid, uninsured, 
Alaskan Native, or Native American
238. Just under half of children in the United States rely on 
VFC
239. However, some commentators worry that individuals who do not qualify for assistance 
from these programs or live in states where funding is insufficient may be unable to afford the 
vaccine. A decrease in expense is particularly important because the vaccine’s $360 price tag, 
making Gardasil© one of the most expensive vaccines ever offered, is excessive for many of the 
individuals who are most in need of receiving the three-dose series
240. Latina, African American, 
and Asian women are significantly more likely to contract HPV and cervical cancer than 
Caucasian females, particularly in poorer regions of the United States, but individuals of lower 
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socio-economic status also are less able to pay for the vaccine and less likely to have regular Pap 
tests that can detect the conditions while they still can be treated
241.  
The Hepatitis B vaccine provides an apt analogy. When Merck’s Hepatitis B vaccine first 
was introduced, ACIP and the CDC recommended it only for high-risk groups, such as 
intravenous drug users and men who engaged in sexual activity with other men. Once the 
government determined that vaccine uptake was insufficient, the vaccine was mandated for all 
individuals and now typically is administered to infants, despite the fact that Hepatitis B – like 
HPV – often is transmitted through sexual contact
242. Targeting high-risk populations is difficult, 
and mandating the HPV vaccine solely for Latina, African American, and Asian females likely 
would be difficult to enforce and lead to strong legal challenges. Rothman and Rothman take 
issue with the universal, rather than racially- or socioeconomically-focused, application of the 
vaccine mandate and Merck’s marketing strategies. In particular, they disapprove of the manner 
in which Merck’s “One Less” advertisements mislead viewers into believing that all girls are at 
equal risk for contracting HPV and developing cervical cancer
243.  
However, Pinker stresses that statistical probabilities at the population level are not 
appropriate predictions of characteristics at the individual level
244. Thus, instead of hindering the 
ability of individuals who do not need the vaccine to opt-out of its administration, girls should be 
allowed to decide whether receiving the vaccine is appropriate for them. Since state legislatures 
were willing to consider, and in some cases enact, legislation specific to the HPV vaccine, it 
likewise seems reasonable to propose that state legislatures approve an opt-out provision for 
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minors that is specific to the HPV vaccine. Such a provision would allow minors to opt-out of 
receiving Gardasil© regardless of their parents’ views, thereby promoting individual autonomy 
and avoiding the danger of requiring individuals to opt-out of receiving all vaccines if they 
actually desire to avoid only Gardasil©. 
CONCLUSION 
  The HPV vaccine represents a breakthrough in cancer prevention. Even groups that are 
adamantly opposed to making receipt of the HPV vaccine mandatory do not object to the 
availability of the vaccine
245. Gardasil© has the potential to prevent the eleventh most common 
form of cancer in women in the United States and second most common form of cancer in 
women in the world, as well as the most common STI in the United States. However, the 
possibility of achieving these impressive results did not necessarily justify, in scientific and 
medical terms, the rapid mobilization of political forces in support of a vaccine mandate. Neither 
the public nor public health officials was included in the conversation regarding whether to 
impose mandates at the state level for a disease that cannot be transmitted via casual contact. 
Furthermore, the addition of such a controversial vaccine to the mandatory vaccination schedule 
may have a lasting impact on public acceptance and receipt of other vaccines as well as public 
trust in government. 
Girls are taught from a young age the importance of being able to say “no,” and they are 
told that such a statement will have an effect on one’s interlocutor. The concept of consent 
permeates American culture in the context of sexuality and control over one’s body. Therefore, it 
is particularly ironic that a vaccine that protects against a disease that can be transmitted only 
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through intimate, sexual contact could be mandated. Such a move denies the power of saying no, 
both to the vaccine and to sexual activity, since a mandate assumes that no female actually will 
say no to the behavior that can cause the disease against which Gardasil© protects. 
  States are granted the power to determine which vaccines are mandated, a requirement 
only parents have the authority to avoid. However, research in the field of developmental 
psychology suggests that individuals over the age of 14, and possibly even as young as 9, are 
competent to make medical decisions, or at least participate substantially in making choices 
regarding their medical treatment. Legal literature analyzing age of consent laws and the 
competency of minors demonstrates the disconnect between the legal presumption of 
incompetence and the actual abilities of individuals younger than 18. These articles focus on 
individualized treatments for which the patients’ parents must provide – or withhold – consent, 
rather than therapies that have been mandated. Nevertheless, their arguments still are relevant. 
The targeted recipients of Gardasil© should have been given a choice whether to receive the 
vaccine, and this choice should have been informed by more comprehensive and neutrally 
presented scientific and medical evidence. Advertisements that do not mention the primary mode 
of transmission of the conditions against which the vaccine protects do not adequately inform 
potential consumers of the purpose of the product. In addition, providing the public with 
educational materials before, rather than simultaneously or after, mandating the vaccine can 
increase acceptance of the vaccine. This information also can raise awareness among females 
outside of the targeted age group who otherwise will continue to lack knowledge of the 
conditions that Gardasil© prevents. 
  According to legal precedent governing which types of vaccines may be mandated, 
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Gardasil© is available as a voluntary therapy, minors should be able to choose whether to 
receive this vaccine. States already have carved out exceptions to their age of consent laws for 
issues relating to sexual activity, such as treatment for VDs and receipt of some forms of 
contraception. Despite the fact that it is a vaccine, Gardasil© is more comparable to these 
interventions than to vaccinations that protect against polio or smallpox. Placing Gardasil© in 
the same category as treatment for VDs acknowledges that only volitional behavior can lead to a 
need for the protection conveyed by the vaccine and avoids the danger that invoking general 
vaccine opt-out provisions can cause.  
If Merck is successful in establishing additional mandates, then the legislation related to 
Gardasil© should allow the targeted minors to opt-out instead of their parents. Some pre-
adolescent and adolescent girls will recognize the benefits that Gardasil© can convey even if 
their parents do not approve of this vaccination, while other girls will know that they do not need 
this treatment despite their parents’ assertions to the contrary. Contrary to Merck’s commercials, 
there are at least four ways to be one less: use of condoms, abstinence, a sexual relationship with 
only one uninfected partner, or receipt of the vaccine
246. These methods have varying levels of 
success, and the preferred strategy should be chosen by the individual who will need to live with 
the direct consequences. 
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